SBIR/STTR Research Award
HHSN261201400038C;SBIR TOPIC 326 DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS;PROJECT TITLE: CROSSING THE BBB AND TARGETING CSCS FOR GBM THERAPY;CONTRACT PERFORMANCE PERIOD 09
Award amount
$222,900Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- SYNERGENE THERAPEUTICS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- W8E3G5851JK4
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
Not Available
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- TAS::75 0849::TAS - SYNERGENE, INC SBIR PHASE II OPTION PERIOD
- SBIR TOPIC 266 - A TARGETED NANOCOMPLEX FOR EARLY DETECTION OF LUNG CANCER
- TARGETED NANOCOMPLEXED IRON OXIDE FOR EARLY DETECTION WITH CONCURRENT HYPERTHERMI
- A Tumor-Specific Nanoimmunocomplex Markedly Improves MR Imaging
- A Dual Molecular/Tumor Targeting Therapy for PanCa
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
11 SBIR/STTR records share this UEI (1999–2014). Reported award amounts total $3,397,580. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services